AR030647A1 - Composicion farmaceutica con actividad de agua especifica - Google Patents

Composicion farmaceutica con actividad de agua especifica

Info

Publication number
AR030647A1
AR030647A1 ARP010104285A ARP010104285A AR030647A1 AR 030647 A1 AR030647 A1 AR 030647A1 AR P010104285 A ARP010104285 A AR P010104285A AR P010104285 A ARP010104285 A AR P010104285A AR 030647 A1 AR030647 A1 AR 030647A1
Authority
AR
Argentina
Prior art keywords
water activity
pharmaceutical composition
specific water
composition
host
Prior art date
Application number
ARP010104285A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR030647A1 publication Critical patent/AR030647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion que comprende: (a) uno o más agentes biologicamente activos; y (b) un excipiente líquido no acuoso; en donde se proporciona una composicion que inmediatamente después de fabricada puede administrarse a un huésped de manera tal que uno o más agentes biologicamente activos se liberan al huésped y en donde dicha composicion se ha ajustado para que tenga una actividad de agua entre aproximadamente 0,2 y aproximadamente 0,5.
ARP010104285A 2000-09-12 2001-09-11 Composicion farmaceutica con actividad de agua especifica AR030647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23186800P 2000-09-12 2000-09-12

Publications (1)

Publication Number Publication Date
AR030647A1 true AR030647A1 (es) 2003-08-27

Family

ID=22870931

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104285A AR030647A1 (es) 2000-09-12 2001-09-11 Composicion farmaceutica con actividad de agua especifica

Country Status (11)

Country Link
US (1) US20020068065A1 (es)
EP (1) EP1317252A2 (es)
JP (1) JP2004508418A (es)
AR (1) AR030647A1 (es)
AU (1) AU2001288322A1 (es)
BR (1) BR0112878A (es)
CA (1) CA2416563A1 (es)
MX (1) MXPA03002056A (es)
PE (1) PE20020423A1 (es)
WO (1) WO2002022171A2 (es)
ZA (1) ZA200300611B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3691459B2 (ja) * 2002-06-14 2005-09-07 久光メディカル株式会社 粉末状吸入剤組成物
US7659061B2 (en) * 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
EP1651210A1 (en) * 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
BRPI0922041A8 (pt) * 2008-11-19 2022-08-16 Merial Ltd Formulações compreendendo ceftiofur e cetoprofeno ou cetiofur e álcool benzílico.
US10772343B2 (en) 2014-11-19 2020-09-15 Kansas State University Research Foundation Chemical mitigants in animal feed and feed ingredients
KR20190019945A (ko) * 2016-06-22 2019-02-27 디에스엠 아이피 어셋츠 비.브이. 안정한 프로바이오틱 현탁액

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK242083D0 (da) * 1983-05-27 1983-05-27 Hansens Chr Bio Syst Vaginalkapsler
ES2033464T3 (es) * 1987-09-04 1993-03-16 The Procter & Gamble Company Composiciones de relleno que contienen psyllium.
US5143728A (en) * 1987-09-04 1992-09-01 The Procter & Gamble Company Psyllium-containing filling compositions and methods
FR2737122B1 (fr) * 1995-07-25 1997-09-12 Oreal Composition stable contenant de l'acide ascorbique
FR2742354B1 (fr) * 1995-12-15 1998-01-23 Oreal Emulsion e/h/e stable contenant un actif cosmetique et/ou dermatologique sensible a l'eau

Also Published As

Publication number Publication date
ZA200300611B (en) 2004-04-22
AU2001288322A1 (en) 2002-03-26
JP2004508418A (ja) 2004-03-18
WO2002022171A2 (en) 2002-03-21
EP1317252A2 (en) 2003-06-11
MXPA03002056A (es) 2003-07-24
US20020068065A1 (en) 2002-06-06
WO2002022171A3 (en) 2003-01-16
CA2416563A1 (en) 2002-03-21
BR0112878A (pt) 2003-07-01
PE20020423A1 (es) 2002-05-11

Similar Documents

Publication Publication Date Title
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
AR092919A2 (es) Composicion farmaceutica liquida
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
BR9714310A (pt) Composição farmacêutica
ES2159591T3 (es) Composicion de liberacion controlada.
ID27504A (id) Formulasi oral baru
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
ES2182357T3 (es) Nueva utilizacion de budesonide y formoterol.
MY124695A (en) Novel composition and use.
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
NO20022334D0 (no) Ny sammensetning og anvendelse
RU92004549A (ru) Высокодозированные формы коллагеназы для наружного применения
AR013117A1 (es) Una composicion farmaceutica solida en forma de comprimido que comprende un derivado de benzofurano con actividad antiarritmica adaptada para administracion oral
NZ514248A (en) Pharmaceutical composition in a unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
SE8701921L (sv) Ny farmaceutisk anvendning
ES2194003T3 (es) Huperzina a racemica.
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
ES2099021B1 (es) Composicion farmaceutica que tiene actividad analgesica.
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
IS6654A (is) Stöðugt gabapentín með pH innan stýrðra marka
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
AR030648A1 (es) Composicion farmaceutica con excipiente modificado
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
BR0314804A (pt) Forma de dosagem de liberação modificada

Legal Events

Date Code Title Description
FB Suspension of granting procedure